Effects of Selenium and Melatonin on Ocular Ischemic Syndrome
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
ABSTRACT:
PURPOSE: To determine the effects of selenium, melatonin and selenium + melatonin
administered for one month on anterior chamber (AC ) malondialdehyde (MDA) and AC glutathione
(GSH) levels in patients with Ocular ischemic syndrome.
MATERIAL AND METHODS: Thirtyfive patients were included in the study. Study groups were
formed as follows: 1-Control group, 2-Ischemia group 3-Selenium Ischemia group, 4-Melatonin
Ischemia group, 5-Selenium + Melatonin + Ischemia group. AC samples were obtained. MDA and
GSH levels in AC samples were evaluated.
RESULTS : MDA levels were significantly increased in ischemia groups. Selenium and melatonin
supplementation resulted in reduction of MDA levels and significant increase in GSH values.
DISCUSSION: Increased lipid peroxidation associated with ischemia of the anterior segment has
been prevented by selenium and melatonin supplementation.
KEYWORDS: Ocular ischemic syndrome, selenium, melatonin, MDA, GSH